PD-1/PD-L1 inhibitors

DRUG4 trials

Sponsors

Shanghai Pulmonary Hospital, Shanghai, China, Hunan Province Tumor Hospital, Chuangzhen Chen

Conditions

Borderline Resectable CarcinomaChemotherapyEsophageal Squamous Cell Carcinoma (ESCC)Immune Checkpoint BlockadeImmune Checkpoint InhibitorInfluenza VaccineLung CancerMetastatic Malignant Solid Neoplasm

Phase 2

Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Solid Tumors

CompletedNCT06076135

Chuangzhen ChenImmune Checkpoint Blockade, Metastatic Malignant Solid Neoplasm, Radiotherapy +1

Start: 2023-12-26End: 2026-05-10Updated: 2026-07-30

Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma

RecruitingNCT07339488

Chuangzhen ChenBorderline Resectable Carcinoma, Chemotherapy, Esophageal Squamous Cell Carcinoma (ESCC) +4

Start: 2025-12-05End: 2028-11-01Target: 43Updated: 2026-06-18

Unknown Phase

Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors

Shanghai Pulmonary Hospital, Shanghai, ChinaInfluenza Vaccine, Non Small Cell Lung Cancer

Start: 2020-06-01End: 2023-05-31Target: 160Updated: 2020-04-21

The Prediction Biomarkers of Survival Outcome for Severe Immune-related Hepatitis

CompletedNCT05326906

Hunan Province Tumor HospitalLung Cancer

Start: 2018-05-01End: 2022-05-01Updated: 2022-05-16